Learn about FILSPARI, a medication indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Understand the risks of hepatotoxicity and embryo-fetal toxicity associated with FILSPARI and the requirements of the restricted distribution program, FILSPARI REMS. Discover the role of prescribers and the contraceptive options available for patients who can become pregnant.
Learn about FILSPARI REMS, a prescription medicine for slowing kidney function decline in adults with IgAN. Understand the risks, enrollment process, birth control options, and the purpose of the REMS program. Ensure safety with this Risk Evaluation and Mitigation Strategy.
Discover the comprehensive FILSPARITM REMS Prescriber and Pharmacy Guide for Sparsentan Prescription and Dosage. Learn about the product specifications, usage instructions, and requirements for safe administration, including liver and pregnancy testing protocols.
Discover the specifications and usage instructions for REMS Traveres Safari Bags featuring FILSPARI, an effective treatment containing Sparsentan to reduce protein levels in adults with primary immunoglobulin A nephropathy (IgAN). Learn about the risks, FDA-required REMS program, and monitoring guidelines for this medication.
